#digitaldrugdesign search results
Exicure is excited to announce that Elias Papadimas has been promoted to Chief Accounting Officer. Congratulations Elias! #DigitalDrugDesign
Exicure has been granted two Fast Track Designations for #cavrotolimod (AST-008) from the @US_FDA: bit.ly/39ndi3q #DigitalDrugDesign
Portfolio news: Congratulations to @exicure CEO, David Giljohann, for being named to Crain’s Chicago Business 40 Under 40 Class of 2019! @CrainsChicago #DigitalDrugDesign #ccb40s bit.ly/2qfEVc7
Exicure today announced presentations at TIDES EU and Neuroscience 2021: bit.ly/3EoP1aT #DigitalDrugDesign #SfN21
Exicure granted Orphan Drug Designation for #cavrotolimod from the US #FDA : bit.ly/3uTcMEm #DigitalDrugDesign
Exicure today announced participation in TIDES USA 2021 and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society: bit.ly/39731bV #OTS #DigitalDrugDesign
Exicure announces issuance of two new U.S. patents and a new patent allowance further strengthening its intellectual property position and coverage for the therapeutic product candidate #cavrotolimod: bit.ly/3mBVrdx #DigitalDrugDesign
Exicure announces agenda for upcoming #neuroscience pipeline update at Virtual R&D Day on Thursday, January 7th: bit.ly/3pTeKBj #DigitalDrugDesign
Exicure today announced presentations at the 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs) and the International OligonucIeotides and Peptides Conference (IOPC) 2021: bit.ly/3AiJU9R #DigitalDrugDesign
Exicure has announced that researchers at @IINanoNU utilized Exicure's licensed first generation gold-nanoparticle SNA technology in an investigator-initiated trial for the treatment of #glioblastoma: bit.ly/3rH4Jbx #DigitalDrugDesign
Don’t forget to register for our virtual R&D day on Thursday, July 15 from 10:00-11:00am ET to hear Exicure’s CEO, @giljohann, showcase the company’s #neuroscience pipeline. To register for the event, visit: bit.ly/3k3EPO2 #DigitalDrugDesign
Exicure today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress: bit.ly/3jHx3ry #DigitalDrugDesign
Looking to join Exicure in developing a new class of immunomodulatory and gene silencing drugs? We currently have 2 Associate Director positions open and would love for you to join the Exicure team! Visit bit.ly/3dyhnDk to learn more & apply. #hiring #DigitalDrugDesign
Exicure has announced a presentation & participation in 1x1s at the 2021 #BIOCEO & Investor Digital Conference, February 16-18, 2021: bit.ly/3j6ZpuE #DigitalDrugDesign
Exicure has announced a virtual R&D Day on Thursday, July 15, 2021 to showcase the company's #neuroscience pipeline, including its lead program for #FriedreichsAtaxia, XCUR-FXN. To register for the event, visit: bit.ly/3k3EPO2 #DigitalDrugDesign
Exicure’s CEO David Giljohann is speaking at the 13th Annual LD Micro Main Event investor conference on Monday, Dec 14 at 11 a.m. EST. bit.ly/3a3hJCi $XCUR #digitaldrugdesign
Excited to announce that @exicure has dosed the first patient in the Phase 2 dose expansion portion of the Cavrotolimod (AST-008) trial. bit.ly/2N4gxlC #DigitalDrugDesign #merkelcellcarcinoma
Check out our latest blog exploring how experimental data bridges can help with digital drug design, enabling new discoveries, and minimizing the risks. Click to learn more: hubs.ly/Q01N8z8V0 #DigitalDrugDesign #StructuralData
Exicure CEO @giljohann will join @JillMalandrino on @Nasdaq’s #TradeTalks on Thursday, December 24, to discuss the #nanotechnology, #digitaldrugdesign and DNA medicine work being done at Exicure. The interview will be available at: bit.ly/3pm2Gbv
Check out our latest blog exploring how experimental data bridges can help with digital drug design, enabling new discoveries, and minimizing the risks. Click to learn more: hubs.ly/Q01N8z8V0 #DigitalDrugDesign #StructuralData
Exicure today announced presentations at TIDES EU and Neuroscience 2021: bit.ly/3EoP1aT #DigitalDrugDesign #SfN21
Check out this @sciam OpEd by Exicure Co-founder @CHADNANO about the successes in #nanotechnology and #nanochemistry research over the past two decades. #DigitalDrugDesign
"There is a beautifully simple principle at the heart of modern nanotechnology research. Bulk materials become brand-new when miniaturized or restructured at the nanoscale." | Commentary scientificamerican.com/article/a-big-…
Exicure today announced presentations at the 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs) and the International OligonucIeotides and Peptides Conference (IOPC) 2021: bit.ly/3AiJU9R #DigitalDrugDesign
Exicure today announced participation in TIDES USA 2021 and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society: bit.ly/39731bV #OTS #DigitalDrugDesign
Exicure today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress: bit.ly/3jHx3ry #DigitalDrugDesign
Don’t forget to register for our virtual R&D day on Thursday, July 15 from 10:00-11:00am ET to hear Exicure’s CEO, @giljohann, showcase the company’s #neuroscience pipeline. To register for the event, visit: bit.ly/3k3EPO2 #DigitalDrugDesign
Exicure has announced a virtual R&D Day on Thursday, July 15, 2021 to showcase the company's #neuroscience pipeline, including its lead program for #FriedreichsAtaxia, XCUR-FXN. To register for the event, visit: bit.ly/3k3EPO2 #DigitalDrugDesign
Exicure CEO, @giljohann, will present a company update as well as participate in a series of 1x1 meetings at the @LadenburgLTS 2021 Healthcare Conference on July 13, 2021: bit.ly/3qvW3Fe #DigitalDrugDesign
Exicure is excited to announce that Elias Papadimas has been promoted to Chief Accounting Officer. Congratulations Elias! #DigitalDrugDesign
Exicure has announced that researchers at @IINanoNU utilized Exicure's licensed first generation gold-nanoparticle SNA technology in an investigator-initiated trial for the treatment of #glioblastoma: bit.ly/3rH4Jbx #DigitalDrugDesign
Exicure granted Orphan Drug Designation for #cavrotolimod from the US #FDA : bit.ly/3uTcMEm #DigitalDrugDesign
Exicure has announced a presentation & participation in 1x1s at the 2021 #BIOCEO & Investor Digital Conference, February 16-18, 2021: bit.ly/3j6ZpuE #DigitalDrugDesign
Looking to join Exicure in developing a new class of immunomodulatory and gene silencing drugs? We currently have 2 Associate Director positions open and would love for you to join the Exicure team! Visit bit.ly/3dyhnDk to learn more & apply. #hiring #DigitalDrugDesign
Exicure has been granted two Fast Track Designations for #cavrotolimod (AST-008) from the @US_FDA: bit.ly/39ndi3q #DigitalDrugDesign
Exicure announces agenda for upcoming #neuroscience pipeline update at Virtual R&D Day on Thursday, January 7th: bit.ly/3pTeKBj #DigitalDrugDesign
@giljohann and @JillMalandrino discussed Exicure’s work on @Nasdaq’s #TradeTalks earlier today: pscp.tv/w/1vAxRwmPNArKl #DigitalDrugDesign
.@exicure CEO @giljohann joins @JillMalandrino on @Nasdaq #TradeTalks to discuss how this combination of technology and medicine is being used to treat cancer and other rare diseases while lowering cost. pscp.tv/w/crNo4jFvUEVM…
Exicure CEO @giljohann will join @JillMalandrino on @Nasdaq’s #TradeTalks on Thursday, December 24, to discuss the #nanotechnology, #digitaldrugdesign and DNA medicine work being done at Exicure. The interview will be available at: bit.ly/3pm2Gbv
Exicure announces issuance of two new U.S. patents and a new patent allowance further strengthening its intellectual property position and coverage for the therapeutic product candidate #cavrotolimod: bit.ly/3mBVrdx #DigitalDrugDesign
Exicure’s CEO David Giljohann is speaking at the 13th Annual LD Micro Main Event investor conference on Monday, Dec 14 at 11 a.m. EST. bit.ly/3a3hJCi $XCUR #digitaldrugdesign
Exicure has been granted two Fast Track Designations for #cavrotolimod (AST-008) from the @US_FDA: bit.ly/39ndi3q #DigitalDrugDesign
Portfolio news: Congratulations to @exicure CEO, David Giljohann, for being named to Crain’s Chicago Business 40 Under 40 Class of 2019! @CrainsChicago #DigitalDrugDesign #ccb40s bit.ly/2qfEVc7
Exicure granted Orphan Drug Designation for #cavrotolimod from the US #FDA : bit.ly/3uTcMEm #DigitalDrugDesign
Exicure has announced that researchers at @IINanoNU utilized Exicure's licensed first generation gold-nanoparticle SNA technology in an investigator-initiated trial for the treatment of #glioblastoma: bit.ly/3rH4Jbx #DigitalDrugDesign
Exicure is excited to announce that Elias Papadimas has been promoted to Chief Accounting Officer. Congratulations Elias! #DigitalDrugDesign
Don’t forget to register for our virtual R&D day on Thursday, July 15 from 10:00-11:00am ET to hear Exicure’s CEO, @giljohann, showcase the company’s #neuroscience pipeline. To register for the event, visit: bit.ly/3k3EPO2 #DigitalDrugDesign
Exicure today announced participation in TIDES USA 2021 and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society: bit.ly/39731bV #OTS #DigitalDrugDesign
Exicure today announced presentations at TIDES EU and Neuroscience 2021: bit.ly/3EoP1aT #DigitalDrugDesign #SfN21
Exicure announces agenda for upcoming #neuroscience pipeline update at Virtual R&D Day on Thursday, January 7th: bit.ly/3pTeKBj #DigitalDrugDesign
Exicure to participate in the 2020 Virtual Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day and the Virtual Fall Investor Summit today: bit.ly/2UwqR9F #DigitalDrugDesign $XCUR
Exicure CEO @giljohann will join @JillMalandrino on @Nasdaq’s #TradeTalks on Thursday, December 24, to discuss the #nanotechnology, #digitaldrugdesign and DNA medicine work being done at Exicure. The interview will be available at: bit.ly/3pm2Gbv
Exicure presents positive clinical data with cavrotolimod at the #SITC20 35th Anniversary Annual Meeting: bit.ly/2JQMiAd #DigitalDrugDesign
Exicure today reported financial results for the quarter ended June 30, 2021 and provided an update on corporate progress: bit.ly/3jHx3ry #DigitalDrugDesign
Looking to join Exicure in developing a new class of immunomodulatory and gene silencing drugs? We currently have 2 Associate Director positions open and would love for you to join the Exicure team! Visit bit.ly/3dyhnDk to learn more & apply. #hiring #DigitalDrugDesign
Exicure announces issuance of two new U.S. patents and a new patent allowance further strengthening its intellectual property position and coverage for the therapeutic product candidate #cavrotolimod: bit.ly/3mBVrdx #DigitalDrugDesign
Exicure has announced a presentation & participation in 1x1s at the 2021 #BIOCEO & Investor Digital Conference, February 16-18, 2021: bit.ly/3j6ZpuE #DigitalDrugDesign
Exicure’s CEO David Giljohann is speaking at the 13th Annual LD Micro Main Event investor conference on Monday, Dec 14 at 11 a.m. EST. bit.ly/3a3hJCi $XCUR #digitaldrugdesign
Exicure today announced presentations at the 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs) and the International OligonucIeotides and Peptides Conference (IOPC) 2021: bit.ly/3AiJU9R #DigitalDrugDesign
Exicure CEO, @giljohann, will present a company update as well as participate in a series of 1x1 meetings at the @LadenburgLTS 2021 Healthcare Conference on July 13, 2021: bit.ly/3qvW3Fe #DigitalDrugDesign
Something went wrong.
Something went wrong.
United States Trends
- 1. Thanksgiving 1.16M posts
- 2. Turkey Day 23.1K posts
- 3. #Thankful 6,024 posts
- 4. #Gratitude 5,912 posts
- 5. Afghanistan 211K posts
- 6. #Grateful 3,328 posts
- 7. Feliz Día de Acción de Gracias 1,608 posts
- 8. Jonathan Groff N/A
- 9. #StrangerThings5 379K posts
- 10. Hoda 2,177 posts
- 11. Gobble Gobble 17.5K posts
- 12. Good Thursday 25.4K posts
- 13. Al Roker N/A
- 14. Taliban 56.2K posts
- 15. DYTD TRAILER 258K posts
- 16. #CalleBatallaYVictoria 6,324 posts
- 17. God for His 20K posts
- 18. Piers 23.4K posts
- 19. Go Lions 1,318 posts
- 20. Asylum 157K posts